ABVX:EPA
Abivax SA
၈၃.၀၅ €
arrow_downward
-၀.၅၄%(-၀.၄၅) 1D
အောက် ၅, GMT+၂ ၁၀:၀၆:၃၁ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
၈၃.၄၀ €
High
၈၃.၄၀ €
Low
၈၂.၆၅ €
Mkt. cap
၇၂၆.၉၄ ဋေ
Avg. vol.
၁.၅၆ သိန်း
Volume
၁.၅၃ သောင်း
52-wk high
၁၃၉.၀၀ €
52-wk low
၆၀.၄၅ €
EPS
-၅.၂၀ €
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
Open
၈၃.၄၀ €
High
၈၃.၄၀ €
Low
၈၂.၆၅ €
Mkt. cap
၇၂၆.၉၄ ဋေ
Avg. vol.
၁.၅၆ သိန်း
Volume
၁.၅၃ သောင်း
52-wk high
၁၃၉.၀၀ €
52-wk low
၆၀.၄၅ €
EPS
-၅.၂၀ €
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
News stories
From web sources and news partners
Reuters
·
ပြီးခဲ့သည့် ၁၆ မိနစ်
Panmure Liberum forecasts S&P 500 falling to 5,000, warns bull run nearing end
Trefis
·
ပြီးခဲ့သည့် ၁ နာရီ
S&P 500 Stocks At 52-Week Lows: Friday’s Full List
Kalkine Media
·
ပြီးခဲ့သည့် ၉ မိနစ်
What Comes Next for CleanSpark (NASDAQ:CLSK)?
Yahoo Finance
·
ပြီးခဲ့သည့် ၂ နာရီ
Stock Market: Will S&P 500 Open Up or Down Today?
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees၉၈
Founded၂၀၁၃ ဒီ ၄
Headquarters-
Sector-
Websiteabivax.com